Experimental vaccine aims to stop rare eye cancer from returning

NCT ID NCT01983748

Completed ⭐️ VACCINE ⭐️ Sponsor: University Hospital Erlangen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested a personalized vaccine made from a patient's own immune cells and tumor RNA in 200 people with a high-risk form of eye cancer (uveal melanoma with monosomy 3). After surgery to remove the tumor, half received the vaccine over two years and half were simply observed. The goal was to see if the vaccine could prevent the cancer from coming back and improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Show contact details

Locations

Dept. of Dermatology, University Hospital

Erlangen, Bavaria, 90154, Germany
Städtisches Klinikum

Dessau, 06847, Germany
University Hospital Department of Ophtalmology

Erlangen, Bavaria, 91054, Germany
University Hospital Department of Ophtalmology

Würzburg, Bavaria, 97080, Germany
University Hospital Department of Ophtalmology

Essen, 45122, Germany
University Hospital Department of Ophtalmology

Homburg/Saar, 66421, Germany
University Hospital Department of Ophtalmology

Lübeck, 23538, Germany
University Hospital Department of Ophtalmology

Tübingen, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.